Skip to content

GRAIL, Inc. GRAL Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA

Other financials

Income statement

See full
Revenue$40.8M+28.1%
Operating income-$135.8M+11.6%
Net income-$93.2M+12.3%
EPS (diluted)-$2.29+26.1%

Balance sheet

See full
Cash & equivalents$76.3M-44.4%
Total debt$51.0M-20.7%
Total equity$2.5B+3.6%
Total assets$2.8B-1.5%

Cash flow

See full
Operating cash flow-$87.0M+8.4%
CapEx$503.0K+711%
Free cash flow-$87.5M+8.0%

Valuation

See full
Market cap$2.77B+145%

Profitability

See full
Operating margin-348.7%-153pp
Net margin-253.2%-115pp
FCF margin-187.2%-60.4pp

Returns & leverage

See full
Return on equity-16.1%
Debt / equity0.0×
Current ratio11.7×+2.0×

Where this comes from

Reported directly by GRAIL, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: GRAIL, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about GRAIL, Inc.'s accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GRAIL, Inc.'s accrued expenses and other liabilities?
GRAIL, Inc. (GRAL) reported accrued expenses and other liabilities of -$5.36M in Q1 2026.
How has GRAIL, Inc.'s accrued expenses and other liabilities changed year-over-year?
GRAIL, Inc.'s accrued expenses and other liabilities decreased by 72.8% year-over-year, from -$3.11M to -$5.36M.
What is the long-term trend for GRAIL, Inc.'s accrued expenses and other liabilities?
Over 3 years (2022 to 2025), GRAIL, Inc.'s accrued expenses and other liabilities has grown at a -17.6% compound annual growth rate (CAGR), from $11.56M to $6.46M.